IMPROVING THE LIVES OF PEOPLE WITH NEURODEVELOPMENTAL DISABILITIES Corporate Presentation 2 September 2026 Forward looking statements This presentation contains forward looking statements that involve risks and uncertainties. Although we believe that the expectations reflected in the...
Corporate Presentation, 2 September 2026
Filed with ASX ·
6ix hasn’t read this filing yet.
Neuren Pharmaceuticals Limited on 6ix
Earlier from Neuren Pharmaceuticals
- Dividend/Distribution - NEU
- Investor presentation, 26 August 2026
- Growing royalty anchors Neuren first ever dividend program
- Half Yearly Report and Accounts
- European Commission grants marketing authorisation for DAYBU
Later from Neuren Pharmaceuticals
- Update - Dividend/Distribution - NEU
- Pause in Trading
- Trofinetide US patent protections extended to March 2041
- FDA grants Orphan Drug Designation for NNZ-2591 to treat HIE
- Q3 2026 DAYBUE net sales up 39%, full year guidance upgraded
